Advertisement

Annals of Hematology

, Volume 98, Issue 8, pp 1973–1980 | Cite as

BAM conditioning before autologous transplantation for lymphoma: a study on behalf of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)

  • Jérôme CornillonEmail author
  • Elisabeth Daguenet
  • Jacques-Olivier Bay
  • Adrien Chauchet
  • Gilles Salles
  • Nathalie Contentin
  • Emmanuelle Nicolas-Virelizier
  • Mélanie Mercier
  • Nicolas Vallet
  • Magda Alexis
  • Marie-Lorraine Chrétien
  • Thomas Cluzeau
  • Anne Huynh
  • Chantal Himberlin
  • Véronique Dorvaux
  • Sandy Amorim
  • Caroline Lejeune
  • Régis Peffault de Latour
  • Emmanuel Gyan
Original Article

Abstract

High-dose chemotherapy before autologous transplantation is a therapeutic option as consolidation in primary or relapsed lymphoma. Even if BEAM conditioning is generally used, alternative conditioning regimens have been published. The purpose of this study was to assess the outcome of 177 adult patients with lymphoma whose conditioning treatment included a BAM (busulfan, aracytine, and melphalan) regimen. With a median follow-up of 17.4 months, 2-year estimates of overall survival and progression-free survival for the entire group were 87% and 70.5%, respectively. Mucositis was the main reported complications and infectious episodes were described in 80.2% of patients. According to multivariate analysis, high performance status and age at diagnosis were adverse factors for survival and increased the risk of disease relapse and death. Despite its limitations, this retrospective study suggests that BAM combination is a valid conditioning regimen in lymphoma patients, with an acceptable rate of toxicity.

Keywords

Autologous transplantation Conditioning regimen BEAM BAM Lymphoma 

Notes

Compliance with ethical standards

Conflict of interest

EG received research support from Pierre Fabre. The remaining authors declare that they have no conflict of interest.

Ethical approval

This study was approved by the SFGM-TC scientific council and performed according to the SFGM-TC guidelines and in accordance with the principles of the declaration of Helsinki.

Informed consent

Informed consent was obtained from all subjects.

Supplementary material

277_2019_3704_MOESM1_ESM.doc (36 kb)
Supplementary Table 1 Main extra-hematological toxicities according to WHO scale or CTCAE v4.0. (DOC 35 kb)

References

  1. 1.
    Philip T, Guglielmi C, Hagenbeek A, Somers R, van der Lelie H, Bron D, Sonneveld P, Gisselbrecht C, Cahn JY, Harousseau JL, Coiffier B, Biron P, Mandelli F, Chauvin F (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med 333:1540–1545.  https://doi.org/10.1056/NEJM199512073332305 CrossRefGoogle Scholar
  2. 2.
    Mills W, Chopra R, McMillan A, Pearce R, Linch DC, Goldstone AH (1995) BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin’s lymphoma. J Clin Oncol Off J Am Soc Clin Oncol 13:588–595.  https://doi.org/10.1200/JCO.1995.13.3.588 CrossRefGoogle Scholar
  3. 3.
    Andre M, Henry-Amar M, Pico JL et al (1999) Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin’s disease induction failure: a case-control study. J Clin Oncol 17(1):222–229.  https://doi.org/10.1200/JCO.1999.17.1.222 CrossRefGoogle Scholar
  4. 4.
    Fernandez HF, Escalón MP, Pereira D, Lazarus HM (2007) Autotransplant conditioning regimens for aggressive lymphoma: are we on the right road? Bone Marrow Transplant 40:505–513.  https://doi.org/10.1038/sj.bmt.1705744 CrossRefGoogle Scholar
  5. 5.
    Chen Y-B, Lane AA, Logan BR, Zhu X, Akpek G, Aljurf MD, Artz AS, Bredeson CN, Cooke KR, Ho VT, Lazarus HM, Olsson RF, Saber W, McCarthy PL, Pasquini MC (2015) Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 21:1046–1053.  https://doi.org/10.1016/j.bbmt.2015.02.005 CrossRefGoogle Scholar
  6. 6.
    Salar A, Sierra J, Gandarillas M, Caballero MD, Marín J, Lahuerta JJ, García-Conde J, Arranz R, León A, Zuazu J, García-Laraña J, López-Guillermo A, Sanz MA, Grañena A, García JC, Conde E, GEL/TAMO Spanish Cooperative Group (2001) Autologous stem cell transplantation for clinically aggressive non-Hodgkin’s lymphoma: the role of preparative regimens. Bone Marrow Transplant 27:405–412.  https://doi.org/10.1038/sj.bmt.1702795 CrossRefGoogle Scholar
  7. 7.
    Jo J-C, Kang BW, Jang G, Sym SJ, Lee SS, Koo JE, Kim JW, Kim S, Huh J, Suh C (2007) BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin’s lymphoma patients: comparative analysis of efficacy and toxicity. Ann Hematol 87:43–48.  https://doi.org/10.1007/s00277-007-0360-0 CrossRefGoogle Scholar
  8. 8.
    Damaj G, cornillon J, Bouabdallah K et al (2017) Carmustine replacement in intensive chemotherapy preceding reinjection of autologous HSCs in Hodgkin and non-Hodgkin lymphoma: a review. Nature Publishing Group, London, pp 1–9.  https://doi.org/10.1038/bmt.2016.340 Google Scholar
  9. 9.
    Isidori A, Christofides A, Visani G (2016) Novel regimens prior to autologous stem cell transplantation for the management of adults with relapsed/refractory non-Hodgkin lymphoma and Hodgkin lymphoma: alternatives to BEAM conditioning. Leuk Lymphoma 57:2499–2509.  https://doi.org/10.1016/S0140-6736(15)60165-9 CrossRefGoogle Scholar
  10. 10.
    Brice P, Divine M, Simon D, Coiffier B, Leblond V, Simon M, Voilat L, Devidas A, Morschhauser F, Rohrlich P, André M, Lepage E, Ferme C, SFGM/GELA Study Group (1999) Feasibility of tandem autologous stem-cell transplantation (ASCT) in induction failure or very unfavorable (UF) relapse from Hodgkin’s disease (HD). SFGM/GELA study group. Ann Oncol 10:1485–1488CrossRefGoogle Scholar
  11. 11.
    Jonkhoff AR, De Kreuk AM, Franschman G et al (2002) Granulocyte colony-stimulating factor mobilized whole blood containing over 0.3 x 106/kg CD34+ cells is a sufficient graft in autologous transplantation for relapsed non-Hodgkin’s lymphoma. Br J Haematol 118:90–100CrossRefGoogle Scholar
  12. 12.
    Puig N, de la Rubia J, Remigia MJ et al (2009) Morbidity and transplant-related mortality of CBV and BEAM preparative regimens for patients with lymphoid malignancies undergoing autologous stem-cell transplantation. Leuk Lymphoma 47:1488–1494.  https://doi.org/10.1038/sj.bmt.1704110 CrossRefGoogle Scholar
  13. 13.
    Sharma A, Kayal S, Iqbal S, Malik PS, Raina V (2013) Comparison of BEAM vs. LEAM regimen in autologous transplant for lymphoma at AIIMS. Springerplus 2:489.  https://doi.org/10.1186/2193-1801-2-489 CrossRefGoogle Scholar
  14. 14.
    Kim JE, Lee DH, Yoo C, Kim S, Kim SW, Lee JS, Park CJ, Huh J, Suh C (2011) BEAM or BuCyE high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: a single center comparative analysis of efficacy and toxicity. Leuk Res 35:183–187.  https://doi.org/10.1016/j.leukres.2010.07.016 CrossRefGoogle Scholar
  15. 15.
    Vose JM, Carter S, Burns LJ, Ayala E, Press OW, Moskowitz CH, Stadtmauer EA, Mineshi S, Ambinder R, Fenske T, Horowitz M, Fisher R, Tomblyn M (2013) Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT CTN 0401 trial. J Clin Oncol 31:1662–1668.  https://doi.org/10.1200/JCO.2012.45.9453 CrossRefGoogle Scholar
  16. 16.
    Nieto Y, Popat U, Anderlini P, Valdez B, Andersson B, Liu P, Hosing C, Shpall EJ, Alousi A, Kebriaei P, Qazilbash M, Parmar S, Bashir Q, Shah N, Khouri I, Rondon G, Champlin R, Jones RB (2013) Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin’s lymphoma: effect of the specific high-dose chemotherapy regimen on outcome. Biol Blood Marrow Transplant 19:410–417.  https://doi.org/10.1016/j.bbmt.2012.10.029 CrossRefGoogle Scholar
  17. 17.
    Caballero MD, Rubio V, Rifon J, Heras I, García-Sanz R, Vázquez L, Vidriales B, Cañizo MC, Corral M, Gonzalez M, León A, Jean-Paul E, Rocha E, Moraleda JM, Miguel JFS (1997) BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors. Bone Marrow Transplant 20:451–458.  https://doi.org/10.1038/sj.bmt.1700913 CrossRefGoogle Scholar
  18. 18.
    Bhatia S, Robison LL, Francisco L, Carter A, Liu Y, Grant M, Baker KS, Fung H, Gurney JG, McGlave P, Nademanee A, Ramsay NK, Stein A, Weisdorf DJ, Forman SJ (2005) Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor Study. Blood 105:4215–4222.  https://doi.org/10.1182/blood-2005-01-0035 CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Jérôme Cornillon
    • 1
    Email author
  • Elisabeth Daguenet
    • 1
  • Jacques-Olivier Bay
    • 2
  • Adrien Chauchet
    • 3
  • Gilles Salles
    • 4
  • Nathalie Contentin
    • 5
  • Emmanuelle Nicolas-Virelizier
    • 6
  • Mélanie Mercier
    • 7
  • Nicolas Vallet
    • 8
  • Magda Alexis
    • 9
  • Marie-Lorraine Chrétien
    • 10
  • Thomas Cluzeau
    • 11
  • Anne Huynh
    • 12
  • Chantal Himberlin
    • 13
  • Véronique Dorvaux
    • 14
  • Sandy Amorim
    • 15
  • Caroline Lejeune
    • 1
  • Régis Peffault de Latour
    • 16
  • Emmanuel Gyan
    • 8
  1. 1.Department of Clinical HematologyInstitut de Cancérologie Lucien NeuwirthSaint-Priest-en-JarezFrance
  2. 2.Centre Hospitalo-Universitaire Clermont-FerrandClermont-FerrandFrance
  3. 3.Centre Hospitalier Régional Universitaire BesançonBesançonFrance
  4. 4.Centre Hospitalier Lyon SudLyonFrance
  5. 5.Centre Henri BecquerelRouenFrance
  6. 6.Centre Léon BérardLyonFrance
  7. 7.Centre Hospitalo-Universitaire d’AngersAngersFrance
  8. 8.Centre Hospitalo-Universitaire ToursToursFrance
  9. 9.Centre Hospitalier Régional OrléansOrléansFrance
  10. 10.Centre Hospitalo-Universitaire DijonDijonFrance
  11. 11.Centre Hospitalo-Universitaire NiceNiceFrance
  12. 12.Centre Hospitalo-Universitaire ToulouseToulouseFrance
  13. 13.Centre Hospitalo-Universitaire ReimsReimsFrance
  14. 14.Centre Hospitalier Régional MetzMetzFrance
  15. 15.Département d’Onco-Hématologie adulteHôpital Saint-Louis AP-HPParisFrance
  16. 16.Département d’Hématologie GreffeHôpital Saint-Louis AP-HPParisFrance

Personalised recommendations